Ocular Therapeutix, Inc. (OCUL) vs Palvella Therapeutics, Inc. (PVLA)

Ocular Therapeutix, Inc. and Palvella Therapeutics, Inc. are both Biotechnology companies. Ocular Therapeutix, Inc. and Palvella Therapeutics, Inc. are of similar size ($2.2B and $2.1B). Palvella Therapeutics, Inc. grew revenue faster over the last twelve months: 142.9% against −8.14%. Palvella Therapeutics, Inc. has the higher net margin (0.00% vs −579.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 17 metrics below, Palvella Therapeutics, Inc. leads on 13 and Ocular Therapeutix, Inc. on 4.

Valuation

Metric OCUL PVLA Biotechnology median
P/E n/m n/m 7.88
P/S 41.70 48.46 11.47
P/B 4.17 9.15 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 31.60 42.37 10.73
Earnings yield (14.72%) (3.50%) (28.84%)
Free cash flow yield (11.75%) (1.62%) (23.03%)

Profitability

Metric OCUL PVLA Biotechnology median
Gross margin 87.11% 100.00% 65.16%
Operating margin (603.04%) 0.00% 0.00%
Net margin (579.10%) 0.00% 0.00%
Free cash flow margin (490.07%) 0.00% 0.00%
Return on equity (72.99%) (46.63%) (57.72%)
Return on assets (53.70%) (37.70%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric OCUL PVLA Biotechnology median
Revenue growth (TTM) (8.14%) 142.89% 5.64%
EPS growth (last fiscal year) (16.39%) 52.62% —
Revenue growth, 5-year CAGR 24.45% 8.03% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric OCUL PVLA Biotechnology median
Debt to equity 0.14 0.00 0.00
Current ratio 13.11 21.18 4.73
Net debt to EBITDA 2.51 1.50 0.96

Dividend

Metric OCUL PVLA Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric OCUL PVLA Biotechnology median
Market cap 2.16b 2.10b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack